Generic drugmaker Mylan has officially made its $27bn takeover bid directly to shareholders of the Irish over-the-counter (OTC) firm Perrigo after its board rejected the previous proposal in April.
Under the revised bid, Mylan is offering $75 in cash and 2.3 shares of Mylan for each Perrigo share held, valued at around $187 based on the closing price of Friday.
If the transaction is complete, Perrigo shareholders will own 40% of the combined company.
Scientists at the University of Queensland, Brisbane, Australia, have identified similarities in how the body reacts to mosquito-borne dengue virus and bacterial infections, marking a significant breakthrough in treatment for Dengue fever.
Clinical trials for dengue fever treatment could begin within a year or more with the latest discovery.
University of Queensland Chemistry and Molecular Biosciences head professor Paul Young said: "We have discovered that the dengue virus NS1 protein acts as a toxin in the body, in a similar manner to the way bacterial cell wall products lead to septic shock in bacterial infections.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Ireland-based Endo International has completed the $8.05bn acquisition of US-based Par Pharmaceutical Holdings from private investment firm TPG Capital North America.
The deal adds a quickly growing generics portfolio to its specialty offerings, and positions Endo as one of the five largest generic drug companies in the US based on annual sales.
Endo’s generics portfolio currently includes a range of in-market and R&D stage complex and competitively differentiated dosage forms and delivery systems, with a focus on higher barrier-to-entry and first-to-market products.
London’s Moorfields Eye Hospital has treated the first patient in a clinical trial with a new stem cell derived treatment for wet age-related macular degeneration (AMD).
AMD is the leading cause of blindness in adults globally.
The procedure, which was developed at University College London with funding from the Medical Research Council (MRC), offers hope to those with AMD.
Pfizer has launched a self-injectable contraceptive called Sayana Press (medroxyprogesterone acetate) for women in the UK.
Sayana Press is a combination of a long-acting, reversible contraceptive, and an all-in-one prefilled, single-use, non-reusable Uniject injection system, reducing the need to prepare a needle and syringe.
The company said that each subcutaneous injection prevents ovulation and provides contraception for around 13 weeks.
Researchers at the Washington University School of Medicine in St Louis have found that three antibiotic drugs that are not effective against a drug-resistant staph infection individually can kill the deadly pathogen when used as a trio.
During the research, meropenem, piperacillin and tazobactam were used in a combination to kill methicillin-resistant Staphylococcus aureus (MRSA) in test tubes and laboratory mice, and researchers believe the same three-drug strategy may be effective in humans.
Washington University pathology and immunology associate professor and principal investigator Gautam Dantas said: "MRSA infections kill 11,000 people each year in the US, and the pathogen is considered one of the world’s worst drug-resistant microbes."
India has reportedly rejected US drug-maker Pfizer’s new patent application for rheumatoid arthritis drug, tofacitinib, for the second time.
In an order dated 3 September, India Patent Office assistant controller of patents and designs Bharat NS was quoted by media sources as saying: "After having considered the submissions of the applicant, it is hereby ordered that the invention disclosed and claimed in the application is not considered as an invention under the provisions of the act.
"I do not admit that the claimed compound has enhanced efficacy over the base compound and hence not patentable under Section 3(d) of Patents Act. I therefore, hereby refuse this application."
The UK has called for a nationwide health alert after detecting a highly drug-resistant gonorrhoea outbreak in the north of England.
Gonorrhoea is a venereal disease involving inflammatory discharge from the urethra or vagina.
It is a serious infection of the genital tract in both men and women, caused by a bacterium Neisseria gonorrhoeae, sometimes called gonococcus.